The Wortovy Maker Novo Nordisk to reduce around 9,000 jobs
In Waterbury, Vermont, USA, on Monday, April 28, 2025, arranged Wegovy Injection pens.
Shelby Knowles | Bloomberg | Getty pictures
The Danish pharmaceutical giant Novo Nordisk announced the plans to cut around 9,000 roles or around 11.5% of its global workforce on Wednesday.
“Novo Nordisk announced a company -wide transformation today to simplify its organization, to improve the speed of decision -making and to re -assign the resources for the company’s growth opportunities in diabetes and obesity,” it says in a statement that the medication has weight loss.
“As part of the transformation, Novo Nordisk intends to reduce the global workforce by around 9,000 of the 78,400 positions in the company, whereby around 5,000 reductions are expected in Denmark.”
The shares rose by 2.5% at 8:18 a.m. London (3:18 a.m. et) and collected earlier losses.
The company said that reducing school statements would encourage a one-off price of 8 billion Danish crown ($ 1.26 billion).
Due to the one -off costs, the company now expects constant exchange rates of 4% to 10%.
The overhaul marks the first major step of CEO and President Mazia Mike Dustdar, who took over the management of the pharmaceutical giant last month after Lars Fruergaard Jørgensen’s surprise.
Novo Nordisk, once the first scope in weight loss medication, has difficulty struggling in the market share of the most important US region-in ment of a number of problems in the supply chain and increased competition from rivals Eli Lilly and cheaper weight loss medication.
In the meantime, the company has difficulty shaking the negative mood according to a number of disappointing test results for the native generation of the next generation of Cagrisema Cagrisema.
“Our markets develop, especially in obesity, since they have become more competitive and consumers.
driven. Our company also has to develop further. This means conveying an increased performance-related culture, using our resources more and more effectively and prioritizing investments where you have the greatest effects-our leading therapy areas, “said Doustdar in a statement.
While an investor investor in July, who confirmed his appointment, Doustdar had said that he took on the role with a feeling of “urgency” and three important priorities. This included the defense of the leadership of Novo in diabetes and obesity, the promotion of a high -performance culture and the realignment of the cost base of the company and the increase in efficiency.
